1. Home
  2. SRPT vs RILYP Comparison

SRPT vs RILYP Comparison

Compare SRPT & RILYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • RILYP
  • Stock Information
  • Founded
  • SRPT 1980
  • RILYP 1973
  • Country
  • SRPT United States
  • RILYP United States
  • Employees
  • SRPT N/A
  • RILYP N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • RILYP Investment Managers
  • Sector
  • SRPT Health Care
  • RILYP Finance
  • Exchange
  • SRPT Nasdaq
  • RILYP Nasdaq
  • Market Cap
  • SRPT 1.7B
  • RILYP N/A
  • IPO Year
  • SRPT 1997
  • RILYP N/A
  • Fundamental
  • Price
  • SRPT $17.97
  • RILYP $4.71
  • Analyst Decision
  • SRPT Buy
  • RILYP
  • Analyst Count
  • SRPT 25
  • RILYP 0
  • Target Price
  • SRPT $61.57
  • RILYP N/A
  • AVG Volume (30 Days)
  • SRPT 7.9M
  • RILYP 30.2K
  • Earning Date
  • SRPT 08-06-2025
  • RILYP 01-01-0001
  • Dividend Yield
  • SRPT N/A
  • RILYP 19.10%
  • EPS Growth
  • SRPT N/A
  • RILYP N/A
  • EPS
  • SRPT N/A
  • RILYP N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • RILYP $854,383,000.00
  • Revenue This Year
  • SRPT $26.87
  • RILYP N/A
  • Revenue Next Year
  • SRPT $3.15
  • RILYP N/A
  • P/E Ratio
  • SRPT N/A
  • RILYP N/A
  • Revenue Growth
  • SRPT 59.15
  • RILYP N/A
  • 52 Week Low
  • SRPT $16.88
  • RILYP $1.73
  • 52 Week High
  • SRPT $154.13
  • RILYP $20.00
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 28.43
  • RILYP 82.79
  • Support Level
  • SRPT $17.31
  • RILYP $2.02
  • Resistance Level
  • SRPT $19.74
  • RILYP $4.78
  • Average True Range (ATR)
  • SRPT 1.04
  • RILYP 0.39
  • MACD
  • SRPT 0.87
  • RILYP 0.31
  • Stochastic Oscillator
  • SRPT 45.83
  • RILYP 97.70

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About RILYP B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

Share on Social Networks: